{"id":"NCT04195906","sponsor":"Sanifit Therapeutics S. A.","briefTitle":"Phase 3 Study of SNF472 for Calciphylaxis","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-12","primaryCompletion":"2022-10-24","completion":"2022-10-24","firstPosted":"2019-12-12","resultsPosted":"2024-02-20","lastUpdate":"2024-02-20"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Calciphylaxis","Calcific Uremic Arteriolopathy"],"interventions":[{"type":"DRUG","name":"Experimental: SNF472","otherNames":[]},{"type":"DRUG","name":"Placebo Comparator: Placebo","otherNames":["Saline"]},{"type":"DRUG","name":"Experimatenl SNF472 (Open-label)","otherNames":[]}],"arms":[{"label":"SNF472 (Double-Blind Period)","type":"EXPERIMENTAL"},{"label":"Placebo (Double-Blind Period)","type":"PLACEBO_COMPARATOR"},{"label":"SNF472 (Open-Label)","type":"EXPERIMENTAL"}],"summary":"The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).","primaryOutcome":{"measure":"Absolute Change in the BWAT - CUA Score for the Primary Lesion","timeFrame":"from Baseline to Week 12","effectByArm":[{"arm":"SNF472","deltaMin":-5.3,"sd":5.18},{"arm":"Placebo","deltaMin":-6,"sd":6.17}],"pValues":[{"comp":"OG000 vs OG001","p":"0.877"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":58,"countries":["United States","Belgium","Germany","Poland","Spain","United Kingdom"]},"refs":{"pmids":["39252867","39186385"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":38},"commonTop":["Calciphylaxis","Pain in extremity","Nausea","Fall","Vomiting"]}}